Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook

— Cash and Cash Investments at December 31, 2025 of €116.5 Million and Gross Proceeds of $208 Million from Initial Public Offering (IPO) Expected to Extend Cash Runway into First Half of 2029 —

— Positive Interactions with U.S. Food and Drug Administration (FDA) on Design of Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease (FSCD) —

— On Track to Initiate Phase 2b Study in FSCD with Ontunisertib and Phase 2 Study in Idiopathic Pulmonary Fibrosis (IPF) with AGMB-447 in Second Half of 2026 —

— Topline Data from Open-Label Long-term Extension Study (OLE) Part of STENOVA Study with Ontunisertib in FSCD and from Phase 1b IPF Study Cohort with AGMB-447 Expected in Second Half of 2026 —

Antwerp, Belgium, April 23, 2026Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today reported financial results for the full year period ended December 31, 2025, and confirmed its outlook for 2026.

“2025 was a pivotal year for Agomab, with significant progress across our clinical programs and the positive topline results of the STENOVA Phase 2a study with ontunisertib in FSCD. Our momentum has continued into 2026 with positive Phase 1 results for AGMB-447 in healthy participants and the successful completion of our IPO,” said Tim Knotnerus, Chief Executive Officer of Agomab. “In the second half of this year, we expect the full read-out of the OLE study with ontunisertib in FSCD as well as the topline IPF cohort data of the Phase 1b study with AGMB-447. Based on the positive regulatory interactions on trial design, we are on track to start both the Phase 2b study with ontunisertib in FSCD and Phase 2 study with AGMB-447 in IPF later this year.”

Pierre Kemula, Chief Financial Officer of Agomab, added, “Thanks to the $208 million in gross proceeds raised from our IPO in February 2026, we are well-capitalized and we expect our cash reserves to last into the first half of 2029. With major milestones approaching later this year, we remain laser-focused on delivering on our corporate and clinical strategy.”

Recent Program Highlights and 2026 Anticipated Milestones 

  • Ontunisertib (AGMB-129), a gut-restricted
    small molecule inhibitor of ALK5
    for the treatment of FSCD 
    • We continue to have positive interactions with the FDA to align on the study design of the Phase 2b study with ontunisertib in FSCD and are on track to initiate the study in the second half of 2026.
    • We are progressing the OLE part of the STENOVA study (Part B) with ontunisertib in FSCD patients, with topline results expected in the second half of 2026. The 48-week data may provide important insights into extended treatment with ontunisertib in FSCD patients.
    • As of February 2026, the Data Safety and Monitoring Board has not raised any safety issue and has recommended for the OLE study to continue as per the protocol with 200mg BID ontunisertib for up to 60 weeks.
    • The results of the 12-week placebo-controlled double-blind part of the STENOVA Phase 2a study with ontunisertib in FSCD (Part A) were presented as a late-breaker at the 21st Congress of ECCO (ECCO’26) in Stockholm, Sweden in February 2026. The late-breaking presentation was also featured by Nature Reviews Gastroenterology & Hepatology as one of the highlights of ECCO’26.
  • AGMB-447, an inhaled small molecule inhibitor of ALK5 in development for the treatment of IPF
    • We continue to enroll participants in the IPF cohort of the Phase 1b study with AGMB-447. In this cohort, up to 12 participants with IPF will receive multiple doses of AGMB-447 or placebo over 14 days. We have dosed the first participants, and expect to report topline results in the second half of 2026.
    • We received positive scientific advice from the UK Medicines and Healthcare products Regulatory Agency (MHRA), supporting our planned Phase 2 trial in IPF patients. We are on track to initiate a Phase 2 proof-of-concept study with AGMB-447 in IPF in the second half of 2026.
    • We were granted a patent covering the composition of matter of AGMB-447 by the United States Patent and Trademark Office (USPTO), solidifying the foundational IP for AGMB-447 in the U.S.

Full Year 2025 Financial Results (consolidated)

  • Cash Position: Cash, cash equivalents and short-term cash investments totaled €116.5 million as of December 31, 2025. Subsequently, in February 2026, we completed our IPO, in which we raised gross proceeds of approximately $208 million, including the proceeds from the underwriters’ partial exercise of their overallotment option, before deducting underwriting discounts and commissions and other offering expenses. We expect that our existing cash and cash investments, including the net proceeds from our IPO, will enable us to fund our operating expenses and capital expenditure requirements into the first half of 2029.
  • R&D Expenses: Research and development (R&D) expenses were €48.9 million for the year ended December 31, 2025, as compared with €39.3 million for the year ended December 31, 2024. The increase in R&D expenses of €9.6 million for the year was primarily due to increased clinical trial expenses, which are outsourced activities, specifically for the two lead programs ontunisertib and AGMB-447.
  • G&A Expenses: General and administrative (G&A) expenses were €12.8 million for the year ended December 31, 2025, as compared with €10.1 million for the year ended December 31, 2024. The increase of €2.7 million for the year mainly relates to increased employee benefits, reflecting organizational scaling to support company growth, including stock-based compensation.
  • Net Loss: Net loss was €62.5 million for the full year ended December 31, 2025, compared to €46.3 million for the full year ended December 31, 2024.

Corporate

  • The company has filed its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission (SEC). The Annual Report is available on the Agomab website at https://agomab.com/ and on the SEC’s website at www.sec.gov.
  • The company will hold its Annual General Meeting (AGM) at 4:00pm CEST on May 26, 2026. The convening notice for the AGM as well as all documents relevant for the meeting are available via the Agomab website at https://ir.agomab.com/governance/shareholder-meetings
 
 

Financial performance

Consolidated statement of profit and loss

                   
      For the year ended December 31
(in thousands of €), except per share data           2025      2024      2023
Research and development expenses      (48,877)    (39,310)    (26,311)
General and administrative expenses      (12,791)    (10,133)    (6,097)
Total operating expenses      (61,668)    (49,443)    (32,408)
               
Other operating income      2,393    1,422    1,218
Operating loss      (59,275)    (48,021)    (31,190)
               
Changes in fair value of financial liabilities      (4,857)    848    18,964
Financial expenses      (133)    (357)    (86)
Financial income      1,718    1,267    303
Loss before taxes      (62,547)    (46,263)    (12,009)
               
Income tax (expense)/income      —    (4)    619
Loss for the year      (62,547)    (46,267)    (11,390)
               —
Weighted average number of common shares outstanding      541,126    541,126    541,126
Basic and diluted loss per share (in €)      (143.22)    (107.09)    (35.63)


 

 

 

    For the year ended December 31
(in thousands of €)           2025      2024      2023
Loss for the year      (62,547)    (46,267)    (11,390)
Items that may be reclassified to profit or loss              
Foreign currency translation differences      21    (10)    —
Items that will not be reclassified to profit or loss              
Remeasurement of post-employment benefit obligations      (8)    (73)    —
Other comprehensive income or loss for the year, net of tax      13    (83)    —
Total comprehensive income or loss for the year      (62,534)    (46,350)    (11,390)
 
 
 

Consolidated statement of financial position

      For the year ended per  
       December 31  
(In thousands of €)           2025      2024  
Assets             
Non-current assets             
Intangible assets      20,110    20,110  
Goodwill      8,612    8,612  
Property, plant and equipment      503    619  
Right-of-use assets      1,083    1,373  
Other financial assets      11    12  
Other non-current assets      2,150    1,787  
Total non-current assets      32,469    32,513  
             
Current assets             
Other current assets      4,723    2,386  
Current financial investments      30,096    —  
Cash and cash equivalents      86,418    171,459  
Total current assets      121,237    173,845  
Total assets      153,706    206,358  
             
Equity             
Share capital      223,072    223,072  
Share premium reserve      76,634    76,634  
Retained earnings      (181,714)    (119,181)  
Share-based payment reserves      13,877    8,522  
Other reserves      (967)    (966)  
Equity attributable to the owners of the parent      130,902    188,081  
Total equity      130,902    188,081  
             
Liabilities             
Non-current liabilities             
Non-current lease liabilities      1,005    1,272  
Non-current contingent consideration      3,210    7,879  
Total non-current liabilities      4,215    9,151  
             
Current liabilities             
Current lease liabilities      249    273  
Anti-dilutive warrants      —    —  
Current contingent consideration      6,526    —  
Trade and other payables      10,266    8,052  
Deferred income and accrued charges      1,548    801  
Total current liabilities      18,589    9,126  
Total liabilities      22,804    18,277  
             
Total equity and liabilities      153,706    206,358  
                 
                 
                 

Consolidated statement of cash flows


    For the years ended per December 31
(In thousands of €)      2025      2024      2023
Net loss for the year    (62,547)    (46,267)    (11,390)
Adjustments for non-cash items:              
             
Current income tax expense (income)    —    4    3
Deferred income tax expense (income)    —    —    (622)
Fair value (gain) loss on financial assets    (96)    —    —
Fair value (gain) loss on financial liabilities    4,857    (848)    (18,964)
Depreciation & amortization    219    311    99
Share-based payment expenses    5,355    1,071    2,159
Net foreign exchange losses (gains)    57    231    —
Interest expense    69    77    86
Interest income    (1,614)    (1,218)    (303)
Operating cash flows before movements in working capital    (53,700)    (46,640)    (28,932)
             
movements in working capital:              
             
Decrease/(increase) in other current assets    (2,337)    (315)    1,343
Decrease/(increase) in other non-current assets    (363)    (342)    (331)
Increase/(decrease) in trade and other payables    2,359    (230)    3,686
Increase/(decrease) in deferred income    747    (395)    (580)
             
Income taxes paid    —    (4)    (3)
Interest paid    (69)    (10)    (20)
Interest received    1,622    1,106    245
Net cash flow from /(used in) operating activities    (51,741)    (46,828)    (24,592)
             
Purchases of property, plant and equipment    (4)    (675)    —
Purchase of financial investments    (30,000)    —    40,000
Payment of contingent consideration from previous acquisition    (3,000)    —    —
Net cash flow from /(used in) investing activities    (33,004)    (675)    40,000
             
Repayment of lease liabilities    (338)    (163)    (100)
Proceeds from capital increase    —    97,055    79,871
Share issue costs    —    (129)    (453)
Other financial expense, net    —    —    6
Net cash flow from /(used in) financing activities    (338)    96,762    79,324
             
Net increase/(decrease) in cash and cash equivalents    (85,083)    49,260    94,732
             
Cash and cash equivalents at beginning of year    171,459    122,402    27,670
Effect of foreign exchange rate changes    45    (204)    —
Cash and cash equivalents at end of year    86,418    171,459    122,402
 
 
 

Ontunisertib and AGMB-447 are investigational drugs and not approved by any regulatory authority. Their efficacy and safety have not been established.  

About Agomab

Agomab is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for fibro-inflammatory diseases with high unmet medical need. Agomab’s product candidates are designed to target established potent pathways and utilize organ-restricted approaches, with the aim of increasing efficacy while minimizing safety liabilities. Fostering a culture of excellence, Agomab’s mission is to pioneer therapeutics that aim to resolve fibro-inflammation and restore organ function to enable people with these disorders to live fuller and healthier lives.

Cautionary Note Regarding Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding our expected cash runway, including that we anticipate our cash and cash investments and IPO proceeds will extend our runway into the first half of 2029, our focus on the discovery and development of our pipeline of novel product candidates for fibro-inflammatory disorders, the design of planned Phase 2 clinical trials with ontunisertib for FSCD and AGMB-447 for IPF, our expectation to initiate our Phase 2b Study of ontunisertib in FSCD and our Phase 2 study of AGMB-447 in IPF in the second half of 2026, as well as statements regarding future data readouts, including our expectation to release topline data from the OLE part of the STENOVA study and of the Phase 1b IPF Study Cohort with AGMB-447 in the second half of 2026. Forward-looking statements are based on Agomab’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the results of our clinical trials; expectations regarding the inherent uncertainties associated with the development of novel drug therapies; preclinical and clinical trial and product development activities and regulatory approval requirements for product candidates; the impact of governmental laws and regulations on our business; disruptions caused by our reliance on third party suppliers and service providers; the risk that our expectations and management’s guidance regarding our cash position and other financial estimates may be incorrect; and risks related to geopolitical conflicts and macro-economic events. These and other risks and uncertainties are described more fully in our filings and reports with the SEC, including in our most recent annual report on Form 20‐F filed with the SEC and our subsequent filings and reports filed with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Agomab undertakes no duty to update such information except as required under applicable law. Readers should not rely upon the information in this announcement as current or accurate after its publication date.

Contacts

Investors

Sofie Van Gijsel
VP of Investor Relations
E-Mail: [email protected]
Phone: +1 781 296 1143

Media

Gretchen Schweitzer
Trophic Communications
E-Mail: [email protected] 
Phone: +49 172 861 8540



Kuehn Law Encourages Investors of Marqeta, Inc. to Contact Law Firm

NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) — Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Marqeta, Inc. (NASDAQ: MQ) breached their fiduciary duties to shareholders.

According to a federal securities lawsuit, Insiders at Marqeta caused the company to misrepresent or fail to disclose that: (1) Marqeta understated the regulatory challenges affecting its business outlook; (2) as a result, Marqeta would have to cut its guidance for the fourth quarter of 2024; and (3) as a result, public statements were materially false and/or misleading at relevant times.

If you currently own MQ and purchased prior to February 28, 2024 please contact Justin Kuehn, Esq. by email at [email protected] or call (833) 672-0814.  Kuehn Law pays all case costs and does not charge its investor clients.Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

Why Your Participation Matters:

As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™  

For additional information, please visit Shareholder Derivative Litigation – Kuehn Law.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts:
Kuehn Law, PLLC
Justin Kuehn, Esq.
53 Hill Street, Suite 605
Southampton, NY 11968
[email protected]
(833) 672-0814



Sensus Healthcare to Report First Quarter 2026 Financial Results and Hold Business Update Conference Call on May 7, 2026

Sensus Healthcare to Report First Quarter 2026 Financial Results and Hold Business Update Conference Call on May 7, 2026

BOCA RATON, Fla.–(BUSINESS WIRE)–
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced the company will report financial results for the first quarter of 2026 on Thursday, May 7, 2026. Management will hold a conference call beginning at 4:30 pm Eastern time to review the results, provide a business update and answer questions.

Participants are encouraged to pre-register for the conference call using this link to receive a unique dial-in number to bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Those unable to pre-register can access the conference call by dialing 844-481-2811 (U.S. and Canada Toll Free) or 412-317-0676 (International). Please ask the operator to be connected to the Sensus Healthcare conference call.

The call will be webcast live and can be accessed at this link or in the Investor Relations section of the Company’s website at www.sensushealthcare.com.

About Sensus Healthcare

Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit www.sensushealthcare.com.

Investor Relations Contact

Leigh Salvo

New Street Investor Relations

[email protected]

KEYWORDS: Florida United States North America

INDUSTRY KEYWORDS: General Health Medical Devices Health Radiology Oncology

MEDIA:

Key Tronic Corporation Announces Third Quarter Reporting Date

SPOKANE VALLEY, Wash., April 23, 2026 (GLOBE NEWSWIRE) — KeyTronic Corporation (Nasdaq: KTCC), announced today that it plans to report its results for the third quarter of fiscal 2026 after market close on May 5, 2026.

Key Tronic will host a conference call to discuss its financial results at 2:00 PM Pacific (5:00 PM Eastern) on May 5, 2026. A broadcast of the conference call will be available at www.keytronic.com under “Investor Relations” or by calling 800-330-6710 or +1-213-279-1505 (Access Code: 8278065). A replay will be available at www.keytronic.com under “Investor Relations”.

About Key Tronic

Key Tronic is a leading contract manufacturer offering value-added design and manufacturing services from its facilities in the United States, Mexico, and Vietnam. The Company provides its customers full engineering services, materials management, worldwide manufacturing facilities, assembly services, in-house testing, and worldwide distribution. Its customers include some of the world’s leading original equipment manufacturers. For more information about Key Tronic visit: www.keytronic.com.

CONTACTS: Anthony G. Voorhees Michael Newman
  Chief Financial Officer Investor Relations
  Key Tronic Corporation StreetConnect
  (509) 927-5345 (206) 729-3625
     



Jefferies Financial Group Inc. Announces Pricing of $1,100,000,000 5.125% Senior Notes Due 2031

Jefferies Financial Group Inc. Announces Pricing of $1,100,000,000 5.125% Senior Notes Due 2031

NEW YORK–(BUSINESS WIRE)–
Jefferies Financial Group Inc. (NYSE: JEF) (“JFG”, “we” or “our”) today announced the pricing of its public offering of $1.1 billion aggregate principal amount of 5.125% Senior Notes due 2031 (the “Notes”) with an effective yield of 5.304%, maturing April 28, 2031. The offering is expected to settle on April 28, 2026, subject to the satisfaction of customary closing conditions.

JFG intends to use the net proceeds of the offering for general corporate purposes. Jefferies LLC served as sole global co-ordinator and joint book-runner for the offering of the Notes, SMBC Nikko Securities America, Inc. served as joint book-runner, BNY Mellon Capital Markets, LLC, Citigroup Global Markets Inc. and Natixis Securities Americas LLC served as senior co-managers, and Academy Securities, Inc., AmeriVet Securities, Inc., BBVA Securities Inc., CaixaBank, S.A., Citizens JMP Securities, LLC, Fifth Third Securities, Inc., First Citizens Capital Securities, LLC, HSBC Securities (USA) Inc., Huntington Securities, Inc., Intesa Sanpaolo IMI Securities Corp., M&T Securities, Inc., NatWest Markets Securities Inc., Santander US Capital Markets LLC, Standard Chartered Bank, SG Americas Securities, LLC, UniCredit Capital Markets LLC and U.S. Bancorp Investments, Inc. served as co-managers.

The offering of the Notes is being made pursuant to an effective shelf registration statement, base prospectus and related prospectus supplement. Copies of the prospectus supplement and the base prospectus, when available, may be obtained by contacting Jefferies LLC at toll-free (877) 877-0696, or by email at [email protected]; or SMBC Nikko Securities America, Inc. at toll-free (888) 868-6856, or by email at [email protected]. Investors may also obtain these documents for free by visiting EDGAR on the Securities and Exchange Commission’s (“SEC”) website at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About Jefferies Financial Group Inc.

Jefferies (NYSE: JEF) is one of the world’s leading full-service investment banking and capital markets firms. We primarily serve public companies, private companies, and their sponsors and owners, institutional investors, and government entities. Our services are enhanced by our relentless client focus, our differentiated insights and a flat and nimble operating structure.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements about our future and statements that are not historical facts. These forward-looking statements are typically identified by such words as “believe,” “expect,” “anticipate,” “may,” “intend,” “outlook,” “will,” “estimate,” “forecast,” “project,” “should,” and other similar words and expressions, and are subject to numerous assumptions, risks and uncertainties, which will change over time. Forward-looking statements may contain beliefs, goals, intentions and expectations regarding revenues, earnings, operations, arrangements and other results, and may include statements of future performance, plans, and objectives. Forward-looking statements also include statements pertaining to our strategies for future development of our businesses and products. Forward-looking statements speak only as of the date they are made; we do not assume any duty, and do not undertake, to update any forward-looking statements. Furthermore, because forward-looking statements represent only our belief regarding future events, many of which by their nature are inherently uncertain, the actual results or outcomes may differ, possibly materially, from the anticipated results or outcomes indicated in these forward-looking statements. Information regarding important factors, including risk factors that could cause actual results or outcomes to differ, perhaps materially, from those in our forward-looking statements, is contained in reports we file with the SEC, including our Quarterly Report on Form 10-Q for the quarter ended February 28, 2026. You should read and interpret any forward-looking statement together with reports we file or furnish with the SEC. Past performance may not be indicative of future results. Different types of investments involve varying degrees of risk. Therefore, it should not be assumed that future performance of any specific investment or investment strategy will be profitable or equal the corresponding indicated performance level(s).

For inquiries, please contact:

Jonathan Freedman

Head of Marketing and Communications

Jefferies Financial Group Inc.

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Banking Asset Management Professional Services Finance

MEDIA:

Logo
Logo

TEN Ltd. Announces an Up to Five-Year Charter Extension of Two DP2 Shuttle Tankers


$4.0 billion in minimum fleet revenue-backlog


Tanker markets continue at record levels

ATHENS, Greece, April 23, 2026 (GLOBE NEWSWIRE) — TEN Ltd. (“TEN” or the “Company”) (NYSE: TEN) today announced the employment extension for two DP2 shuttle tankers, in direct continuation of the existing charters which commenced at delivery back in 2013, for up to five years each. These new charters are scheduled to come into effect upon expiration of the existing 15-year contracts around mid-2028 and are expected to generate gross revenues in excess of $200 million over their duration.

“Since our entry into the shuttle tanker market in 2013 with these two vessels, TEN has become one of the largest operators in that segment with a proforma fleet of 16 modern vessels and growing,” stated Mr. George Saroglou, President of TEN. “TEN continues its tested policy of long partnership with major oil concerns that secure future cash flow growth, strong balance sheet and continuous dividends to reward its shareholders,” Mr. Saroglou concluded.

ABOUT TEN Ltd.

Founded in 1993 and celebrating 33 years as a public company, TEN is one of the first and most established public shipping companies in the world. TEN’s diversified energy fleet currently consists of 83 vessels, including ten DP2 shuttle tankers, three VLCCs, five scrubber-fitted LR1 tankers and one LNG carrier under construction, consisting of a mix of crude tankers, product tankers and LNG carriers totaling approximately 11 million dwt.

ABOUT FORWARD-LOOKING STATEMENTS

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those predicted by such forward-looking statements. TEN undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

For further information, please contact:

Company

Tsakos Energy Navigation Ltd.
George Saroglou
President & COO
+30210 94 07 710
[email protected]

Investor Relations / Media

Capital Link, Inc.
Nicolas Bornozis/ Markella Kara
+212 661 7566
[email protected]



Sports Entertainment Gaming Global Corporation Receives Expected Notice from The NASDAQ Stock Market LLC Pertaining to its Form 10-K of December 31, 2025

FORT WORTH, Texas, April 23, 2026 (GLOBE NEWSWIRE) — On April 17, 2026, Sports Entertainment Gaming Global Corporation (NASDAQ: LTRY; LTRYW) (“SEGG Media” or “the Company”) received a notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of not having timely filed the Form 10-K for the period ended December 31, 2025 with the SEC, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), which requires timely filing of all required periodic financial reports with the SEC.

Additionally, the Notice indicated that under the Nasdaq Listing Rules, the Company may submit a plan to regain compliance with the Listing Rule within 60 days and, following receipt of such plan, Nasdaq may grant, at its sole discretion, an extension of 180 calendar days from the Form 10-K due date or October 12, 2026, for the Company to regain compliance.

While the Company can provide no precise assurances as to timing for filing the 10-K, the Company plans to file the Form 10-K as soon as reasonably possible to regain compliance with the Listing Rule.

About SEGG Media Corporation

SEGG Media (Nasdaq: SEGG, LTRYW) is a global sports, entertainment, and gaming group operating a portfolio of digital assets including Sports.com, Concerts.com, TicketStub.com, Lottery.com, and Veloce Media Group. Focused on immersive fan engagement, ethical gaming, and AI-driven live experiences, SEGG Media is redefining how global audiences interact with the content they love.

Important Notice Regarding Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of present or historical fact included in this press release, regarding the Company’s strategy, future operations, prospects, plans and objectives of management, are forward-looking statements. When used in this Form 8-K, the words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “project,” “initiatives,” “continue,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. The forward-looking statements speak only as of the date of this press release or as of the date they are made. The Company cautions you that these forward-looking statements are subject to numerous risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of the Company. In addition, the Company cautions you that the forward-looking statements contained in this press release are subject to risks and uncertainties, including but not limited to, any future findings from ongoing review of the Company’s internal accounting controls, additional examination of the preliminary conclusions of such review, the Company’s ability to secure additional capital resources, the Company’s ability to continue as a going concern, the Company’s ability to respond in a timely and satisfactory matter to the inquiries by Nasdaq, the Company’s ability to regain compliance with the Bid Price Requirement, the Company’s ability to regain compliance with Nasdaq Listing Rules, the Company’s ability to become current with its SEC reports, and those additional risks and uncertainties discussed under the heading “Risk Factors” in the Form 10-K/A filed by the Company with the SEC on April 22, 2025, and the other documents filed, or to be filed, by the Company with the SEC. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the reports that the Company has filed and will file from time to time with the SEC. These SEC filings are available publicly on the SEC’s website at www.sec.gov. Should one or more of the risks or uncertainties described in this press release materialize or should underlying assumptions prove incorrect, actual results and plans could differ materially from those expressed in any forward-looking statements. Except as otherwise required by applicable law, the Company disclaims any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this press release.



For additional information

SEGG Media
[email protected]
737-587-3391

SEGG Investors
[email protected] 
737-787-3891

Meridian Corporation Reports First Quarter 2026 Results and Announces a Quarterly Dividend of $0.14 per Common Share

MALVERN, Pa., April 23, 2026 (GLOBE NEWSWIRE) — Meridian Corporation (Nasdaq: MRBK) today reported:

  Three Months Ended
(Dollars in thousands, except per share data)(Unaudited) March 31,

2026
  December 31,

2025
  March 31,

2025
Income:          
Net income $ 4,714   $ 7,186   $ 2,399
Diluted earnings per common share   0.39     0.61     0.21
Pre-provision net revenue (PPNR)(1)   10,081     12,584     8,357
(1) See Non-GAAP reconciliation in the Appendix          
           
  • Net income for the quarter ended March 31, 2026 was $4.7 million, or $0.39 per diluted share, down $2.5 million, or 34%, from prior quarter.
  • Pre-provision net revenue1 for the quarter was $10.1 million, an improvement of $1.7 million, or 21%, from Q1’2025.
  • Net interest margin improved to 3.82% for the first quarter of 2026 compared to the prior quarter, while the loan yield declined to 7.03%, and cost of funds declined to 3.04% over the same period.
  • Return on average assets and return on average equity for the first quarter of 2026 were 0.74% and 9.44%, respectively.
  • Total assets at March 31, 2026 were $2.6 billion, compared to $2.6 billion at December 31, 2025 and $2.5 billion at March 31, 2025.
  • Commercial loans, excluding leases, increased $17.9 million, or 1% from prior quarter.
  • On April 23, 2026, the Board of Directors declared a quarterly cash dividend of $0.14 per common share, payable May 11, 2026 to shareholders of record as of May 4, 2026.

Christopher J. Annas, Chairman and CEO commented:

“Meridian’s first quarter 2026 earnings totaled $4.7 million, nearly doubling from Q1’2025, resulting from continued improvement in the net interest margin to 3.82% for the first quarter 2026 from 3.46% in Q1’2025. The margin improvement is coming from deposit repricing and some repositioning in the deposit base. SBA loan sale income was down significantly after a management change, but we expect a rebound towards year end. Mortgage banking income (loss) was similar to Q1’2025 with seasonality, and if housing inventory continues to improve we’ll achieve increased originations this year. Pre‑provision net revenue increased nearly 20% year over year, underscoring the durability of our underlying operating performance.

Credit costs remained elevated during the quarter, driven largely by charge‑offs in our SBA and leasing portfolios that trace back to loans originated during the low‑rate environment of 2020 and 2021. We are actively working these credits through restructurings, liquidations, and recoveries, and more than half of our non‑performing SBA balances carry government guarantees. While the remediation process is neither fast nor linear, we have a focused approach to addressing these exposures.

Commercial loan growth was slower during the quarter, as our C&I group experienced some big payoffs, but we remain confident in achieving another year of double digit growth. Our capital position strengthened further, tangible book value increased, and our balance sheet remains well positioned to absorb credit normalization while continuing to invest in disciplined growth and return capital to shareholders.”

Select Condensed Financial Information

  As of or for the three months ended (Unaudited)
  March 31,

2026
  December 31,

2025
  September 30,

2025
  June 30,

2025
  March 31,

2025
  (Dollars in thousands, except per share data)
Income:                  
Net income $ 4,714     $ 7,186     $ 6,659     $ 5,592     $ 2,399  
Basic earnings per common share   0.40       0.62       0.59       0.50       0.21  
Diluted earnings per common share   0.39       0.61       0.58       0.49       0.21  
Net interest income   23,202       23,627       23,116       21,159       19,776  
                   
Balance Sheet:                  
Total assets $ 2,579,289     $ 2,561,995     $ 2,541,130     $ 2,510,938     $ 2,528,888  
Loans, net of fees and costs   2,185,442       2,170,600       2,162,845       2,108,250       2,071,675  
Total deposits   2,169,960       2,158,128       2,131,116       2,110,374       2,128,742  
Non-interest bearing deposits   243,458       245,377       239,614       237,042       323,485  
Stockholders’ equity   202,933       199,716       188,029       178,020       173,568  
                   
Balance Sheet Average Balances:                  
Total assets $ 2,574,298     $ 2,588,357     $ 2,534,565     $ 2,491,625     $ 2,420,571  
Total interest earning assets   2,472,702       2,495,922       2,443,261       2,404,952       2,330,224  
Loans, net of fees and costs   2,175,981       2,200,626       2,146,651       2,113,411       2,039,676  
Total deposits   2,171,837       2,173,242       2,143,821       2,095,028       2,036,208  
Non-interest bearing deposits   250,203       256,554       253,374       249,745       244,161  
Stockholders’ equity   202,607       192,799       183,242       176,945       174,734  
                   
Performance Ratios (Annualized):                  
Return on average assets   0.74 %     1.10 %     1.04 %     0.90 %     0.40 %
Return on average equity   9.44 %     14.79 %     14.42 %     12.68 %     5.57 %



Income Statement –

First
Quarter
2026
Compared to
Fourth
Quarter
2025
First quarter net income decreased $2.5 million, or 34.4%, to $4.7 million due largely to a decrease in non-interest income of $3.6 million, a decrease in net interest income of $425 thousand, and an increase of $712 thousand in the provision for credit losses, while non-interest expense decreased $1.5 million over the prior quarter. Income tax expense decreased $743 thousand over the prior quarter. Detailed explanations of the major categories of income and expense follow below.

Net Interest income
The rate/volume analysis table below analyzes dollar changes in the components of interest income and interest expense as they relate to the change in balances (volume) and the change in interest rates (rate) of tax-equivalent net interest income for the periods indicated and allocated by rate and volume. Changes in interest income and/or expense related to changes attributable to both volume and rate have been allocated proportionately based on the relationship of the absolute dollar amount of the change in each category.

  Three Months Ended                
(dollars in thousands) March 31,

2026
  December 31,

2025
  $ Change   % Change   Change due
to rate
  Change due
to volume
Interest income:                      
Cash and cash equivalents $ 398   $ 348   $ 50     14.4 %   $ (28 )   $ 78  
Investment securities – taxable   1,847     1,891     (44 )   (2.3 )%     (47 )     3  
Investment securities – tax exempt (1)   396     396         %            
Loans held for sale   338     500     (162 )   (32.4 )%     (16 )     (146 )
Loans held for investment   37,806     39,764     (1,958 )   (4.9 )%     (1,173 )     (785 )
Total loans   38,144     40,264     (2,120 )   (5.3 )%     (1,189 )     (931 )
Total interest income $ 40,785   $ 42,899   $ (2,114 )   (4.9 )%   $ (1,264 )   $ (850 )
Interest expense:                      
Interest-bearing demand deposits $ 1,040   $ 1,186   $ (146 )   (12.3 )%   $ (114 )   $ (32 )
Money market and savings deposits   7,070     7,942     (872 )   (11.0 )%     (844 )     (28 )
Time deposits   7,113     7,454     (341 )   (4.6 )%     (408 )     67  
Total interest – bearing deposits   15,223     16,582     (1,359 )   (8.2 )%     (1,366 )     7  
Borrowings   1,293     1,568     (275 )   (17.5 )%     6       (281 )
Subordinated debentures   994     1,049     (55 )   (5.2 )%     (52 )     (3 )
Total interest expense   17,510     19,199     (1,689 )   (8.8 )%     (1,412 )     (277 )
Net interest income differential $ 23,275   $ 23,700   $ (425 )   (1.79 )%   $ 148     $ (573 )
(1) Reflected on a tax-equivalent basis.                    


Interest income decreased $2.1 million quarter-over-quarter on a tax equivalent basis, driven by lower yields and average balances of interest earning assets. The yield on interest-earnings assets decreased 13 basis points and negatively impacted interest income by $1.3 million, while the average balance of interest earning assets decreased by $23.2 million, impacting interest income by $850 thousand.

Average total loans, excluding residential loans for sale, decreased $24.7 million. The largest driver was a $26.7 million decrease in the average balance of residential loans held for investment due to the sale of mortgages in the prior quarter, along with a decrease in average leases of $4.5 million, and a decrease in SBA loan average balances of $4.0 million. These decreases were partially offset by increases in construction, commercial loans, commercial real estate loans and home equity loans, which on a combined basis increased $11.3 million on average.

Interest expense decreased $1.7 million, quarter-over-quarter, due to a decline in the cost of deposits and borrowings. Interest expense on total deposits decreased $1.4 million, interest expense on borrowings decreased $275 thousand, and interest expense on subordinated debentures decreased by $55 thousand as well. During the period, interest-bearing checking accounts decreased $3.4 million, time deposits increased $11.3 million, while money market and savings deposit balances decreased $3.0 million on average. Borrowings decreased $21.5 million on average. On a rate basis, money market accounts and time deposits experienced a decrease in the cost, with the overall cost of deposits having declined 19 basis points.

Overall the net interest margin improved to 3.82%, compared to the prior quarter, as the decline in cost of funds offset the decline in yield on earning assets.

Provision for Credit Losses
The overall provision for credit losses for the first quarter increased $712 thousand to $4.0 million, from $3.3 million in the fourth quarter. The higher level of provision was largely due to a $373 thousand increase in net charge-offs, combined with an increase in the baseline ACL and qualitative reserve factors on certain loan portfolios.

Non-interest income

The following table presents the components of non-interest income for the periods indicated:

  Three Months Ended        
(Dollars in thousands) March 31,

2026
  December 31,

2025
  $ Change   % Change
Mortgage banking income $ 4,528     $ 5,714     $ (1,186 )   (20.8 )%
Wealth management income   1,729       1,679       50     3.0 %
SBA loan income   150       1,285       (1,135 )   (88.3 )%
Earnings on investment in life insurance   272       248       24     9.7 %
Net loss on sale of MSRs   (159 )     (12 )     (147 )   1225.0 %
Net loss on sale of loans         (184 )     184     (100.0 )%
Net change in the fair value of derivative instruments   (51 )     197       (248 )   (125.9 )%
Net change in the fair value of loans held-for-sale   (380 )     112       (492 )   (439.3 )%
Net change in the fair value of loans held-for-investment   (39 )     86       (125 )   (145.3 )%
Net gain (loss) on hedging activity   18       (22 )     40     (181.8 )%
Net gain on sale of investments AFS         453       (453 )   (100.0 )%
Other   969       1,059       (90 )   (8.5 )%
Total non-interest income $ 7,037     $ 10,615     $ (3,578 )   (33.7 )%


Total non-interest income decreased $3.6 million, or 33.7%, quarter-over-quarter largely due to a $1.2 million decrease in mortgage banking income, and a $1.1 million decline in SBA loan income. Despite a quarter-over-quarter increase of 9 basis points in the margin on mortgage banking, mortgage loan sales decreased by $40.6 million, or 20% from the prior quarter, resulting in a lower level of mortgage banking income for the quarter-ended March 31, 2026. In addition, mortgage segment related fair value and derivative & hedging items declined in total by $701 thousand quarter-over-quarter.

SBA loan income decreased $1.1 million as the volume of SBA loans sold was down $14.1 million to $6.7 million, for the quarter-ended March 31, 2026 compared to the quarter-ended December 31, 2025, while the gross margin on SBA loan sales was 8.5% for the quarter-ended March 31, 2026 compared to 7.4% for the quarter-ended December 31, 2025.

In the prior quarter we recorded a gain on sale of investment securities of $453 thousand, which was not repeated in the quarter ended March 31, 2026. Other non-interest income was down $90 thousand from the prior quarter due to smaller declines in several accounts including ATM, wire transfer and other customer account fees.

Non-interest expense
The following table presents the components of non-interest expense for the periods indicated:

  Three Months Ended        
(Dollars in thousands) March 31,

2026
  December 31,

2025
  $ Change   % Change
Salaries and employee benefits $ 12,386   $ 13,103   $ (717 )   (5.5 )%
Occupancy and equipment   1,183     1,210     (27 )   (2.2 )%
Professional fees   974     1,076     (102 )   (9.5 )%
Data processing and software   1,973     1,981     (8 )   (0.4 )%
Advertising and promotion   692     944     (252 )   (26.7 )%
Pennsylvania bank shares tax   258     224     34     15.2 %
Other   2,692     3,120     (428 )   (13.7 )%
Total non-interest expense $ 20,158   $ 21,658   $ (1,500 )   (6.9 )%


Salaries and benefits overall decreased $717 thousand, primarily due to the variable nature of the mortgage segment along with timing of certain incentive expense, in addition to lower incentive compensation within the banking and wealth management segments compared to the previous quarter-end. Advertising and promotion costs decreased $252 thousand, reflecting a decrease in business development efforts and special events since year-end. Furthermore, other expense decreased $428 thousand mainly because OREO related activities in the prior quarter did not recur in the quarter-ended March 31, 2026.

Balance Sheet –
March 31, 2026
Compared to
December 31, 2025
Total assets increased $17.3 million, or 0.7%, to $2.6 billion as of March 31, 2026 from $2.6 billion as of December 31, 2025.

Portfolio loans grew $15.0 million, or 0.7% quarter-over-quarter. This growth was generated from commercial & industrial loans which increased $15.4 million, or 3.6%, construction loans increased $12.8 million, or 3.9%, while commercial mortgage loans decreased $5.0 million, or 0.6%, and SBA loan balances decreased $5.3 million, or 3.8%. Lease financings also decreased $4.7 million, or 10.2% from December 31, 2025, partially offsetting the above noted loan growth.

Total deposits increased $11.8 million, or 0.5% quarter-over-quarter, led by an increase of $13.8 million in interest-bearing deposits. Money market accounts and savings accounts decreased a combined $9.8 million, non-interest bearing accounts decreased $1.9 million or 0.8%, while interest bearing demand deposits decreased $209 thousand. While borrowings increased $3.5 million, or 3.0% quarter-over-quarter.

Total stockholders’ equity increased by $3.2 million from December 31, 2025, to $202.9 million as of March 31, 2026. Changes to equity for the quarter included net income of $4.7 million, an increase of $424 thousand in other comprehensive income, partially offset by dividends paid of $1.7 million. The Community Bank Leverage Ratio for the Bank was 9.69% at March 31, 2026.

Asset Quality Summary
Non-performing loans increased $656 thousand, to $55.7 million at March 31, 2026 compared to $55.1 million at December 31, 2025, with increases coming from commercial mortgage, land development, and commercial non-performing loans, partially offset by a decrease in non-performing SBA loans, residential mortgage loans, and construction loans. Of the total non-performing loans, $23.9 million were SBA loans, with $12.9 million, or 54.0%, guaranteed by the SBA. The SBA portfolio was subject to the Fed’s rapid rate increase with slightly more than half, 53.7%, of total non-performing SBA loans having been originated in 2020-2021 when rates were lower by over 500 basis points. Despite these changes in non-performing loans, the ratio of non-performing loans to total loans as of March 31, 2026 was unchanged from December 31, 2025 at 2.50%. The ratio of non-performing loans to total loans, excluding the guaranteed portion of the SBA portfolio was 1.92%. As of March 31, 2026 there were specific reserves of $2.8 million against individually evaluated loans, a decrease of $613 thousand from the level of specific reserves as of December 31, 2025.

Net charge-offs increased to $3.9 million, or 0.18% of total average loans for the quarter ended March 31, 2026, compared to net charge-offs of $3.5 million, or 0.16%, for the quarter ended December 31, 2025. First quarter charge-offs consisted of $2.5 million in SBA loans, $149 thousand in commercial loans, $856 thousand in finance receivables, and $745 thousand of small ticket equipment leases. Partially offsetting first quarter charge-offs were recoveries of $407 thousand, mainly related to leases.

The ratio of allowance for credit losses to total loans held for investment was 1.00% as of March 31, 2026, consistent with the 1.00% reported as of December 31, 2025, due to the increase in provision for credit losses discussed above, combined with portfolio loan growth being below 1% for the current quarter.

About Meridian Corporation
Meridian Bank, the wholly owned subsidiary of Meridian Corporation, is an innovative community bank serving Pennsylvania, New Jersey, Delaware, Maryland, and Florida. Through its 17 offices, including banking branches and mortgage locations, Meridian offers a full suite of financial products and services. Meridian specializes in business and industrial lending, retail and commercial real estate lending, electronic payments, and wealth management solutions through Meridian Wealth Partners. Meridian also offers a broad menu of high-yield depository products supported by robust online and mobile access. For additional information, visit our website at www.meridianbanker.com. Member FDIC.

“Safe Harbor” Statement
In addition to historical information, this press release may contain “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements with respect to Meridian Corporation’s strategies, goals, beliefs, expectations, estimates, intentions, capital raising efforts, financial condition and results of operations, future performance and business. Statements preceded by, followed by, or that include the words “may,” “could,” “should,” “pro forma,” “looking forward,” “would,” “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” or similar expressions generally indicate a forward-looking statement. These forward-looking statements involve risks and uncertainties that are subject to change based on various important factors (some of which, in whole or in part, are beyond Meridian Corporation’s control). Numerous competitive, economic, regulatory, legal and technological factors, risks and uncertainties that could cause actual results to differ materially include, without limitation, credit losses and the credit risk of our commercial and consumer loan products; changes in the level of charge-offs and changes in estimates of the adequacy of the allowance for credit losses, or ACL; cyber-security concerns; rapid technological developments and changes; increased competitive pressures; changes in spreads on interest-earning assets and interest-bearing liabilities; changes in general economic conditions and conditions within the securities markets; escalating tariff and other trade policies and the resulting impacts on market volatility and global trade; the impact of uncertain or changing political conditions or any current or future federal government shutdown and uncertainty regarding the federal government’s debt limit; unanticipated changes in our liquidity position; unanticipated changes in regulatory and governmental policies impacting interest rates and financial markets; legislation affecting the financial services industry as a whole, and Meridian Corporation, in particular; changes in accounting policies, practices or guidance; developments affecting the industry and the soundness of financial institutions and further disruption to the economy and U.S. banking system; among others, could cause Meridian Corporation’s financial performance to differ materially from the goals, plans, objectives, intentions and expectations expressed in such forward-looking statements. Meridian Corporation cautions that the foregoing factors are not exclusive, and neither such factors nor any such forward-looking statement takes into account the impact of any future events. All forward-looking statements and information set forth herein are based on management’s current beliefs and assumptions as of the date hereof and speak only as of the date they are made. For a more complete discussion of the assumptions, risks and uncertainties related to our business, you are encouraged to review Meridian Corporation’s filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2025 and subsequently filed quarterly reports on Form 10-Q and current reports on Form 8-K that update or provide information in addition to the information included in the Form 10-K and Form 10-Q filings, if any. Meridian Corporation does not undertake to update any forward-looking statement whether written or oral, that may be made from time to time by Meridian Corporation or by or on behalf of Meridian Bank.

 
MERIDIAN CORPORATION AND SUBSIDIARIES
FINANCIAL RATIOS (Unaudited)
(Dollar amounts and shares in thousands, except per share amounts)
 
  Three Months Ended
  March 31,

2026
  December 31,

2025
  September 30,

2025
  June 30,

2025
  March 31,

2025
Earnings and Per Share Data:                  
Net income $ 4,714     $ 7,186     $ 6,659     $ 5,592     $ 2,399  
Basic earnings per common share $ 0.40     $ 0.62     $ 0.59     $ 0.50     $ 0.21  
Diluted earnings per common share $ 0.39     $ 0.61     $ 0.58     $ 0.49     $ 0.21  
Common shares outstanding   11,874       11,826       11,517       11,297       11,285  
                   
Performance Ratios:                  
Return on average assets(2)   0.74 %     1.10 %     1.04 %     0.90 %     0.40 %
Return on average equity(2)   9.44       14.79       14.42       12.68       5.57  
Net interest margin (tax-equivalent)(2)   3.82       3.77       3.77       3.54       3.46  
Yield on earning assets (tax-equivalent)(2)   6.69       6.82       7.01       6.89       6.83  
Cost of funds(2)   3.04       3.23       3.42       3.52       3.56  
Efficiency ratio   66.66 %     63.25 %     65.15 %     65.82 %     69.16 %
                   
Asset Quality Ratios:                  
Net charge-offs (recoveries) to average loans   0.18 %     0.16 %     0.09 %     0.17 %     0.14 %
Non-performing loans to total loans   2.50       2.50       2.53       2.35       2.49  
Non-performing assets to total assets   2.39       2.38       2.32       2.14       2.07  
Allowance for credit losses to:                  
Total loans and other finance receivables   0.99       0.99       1.01       0.99       1.01  
Total loans and other finance receivables (excluding loans at fair value)(1)   1.00       1.00       1.01       1.00       1.01  
Non-performing loans   38.81 %     39.18 %     39.37 %     41.26 %     39.63 %
                   
Capital Ratios:                  
Book value per common share $ 17.09     $ 16.89     $ 16.33     $ 15.76     $ 15.38  
Tangible book value per common share $ 16.80     $ 16.59     $ 16.02     $ 15.44     $ 15.06  
Total equity/Total assets   7.87 %     7.80 %     7.40 %     7.09 %     6.86 %
Tangible common equity/Tangible assets – Corporation(1)   7.75       7.67       7.27       6.96       6.73  
Tangible common equity/Tangible assets – Bank(1)   9.47       9.41       9.16       8.96       8.61  
Tier 1 leverage ratio – Bank   9.69       9.50       9.41       9.32       9.30  
Common tier 1 risk-based capital ratio – Bank   10.63       10.66       10.52       10.53       10.15  
Tier 1 risk-based capital ratio – Bank   10.63       10.66       10.52       10.53       10.15  
Total risk-based capital ratio – Bank   11.64 %     11.65 %     11.54 %     11.54 %     11.14 %
(1) See Non-GAAP reconciliation in the Appendix                
(2) Annualized                  

 
MERIDIAN CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited)
(Dollar amounts and shares in thousands, except per share amounts)
 
  Three Months Ended
  March 31,

2026
  December 31,

2025
  March 31,

2025
Interest income:          
Loans and other finance receivables, including fees $ 38,144     $ 40,264     $ 36,549  
Securities – taxable   1,847       1,891       1,693  
Securities – tax-exempt   323       323       313  
Cash and cash equivalents   398       348       613  
Total interest income   40,712       42,826       39,168  
Interest expense:          
Deposits   15,223       16,582       16,868  
Borrowings and subordinated debentures   2,287       2,617       2,524  
Total interest expense   17,510       19,199       19,392  
Net interest income   23,202       23,627       19,776  
Provision for credit losses   3,999       3,287       5,212  
Net interest income after provision for credit losses   19,203       20,340       14,564  
Non-interest income:          
Mortgage banking income   4,528       5,714       3,393  
Wealth management income   1,729       1,679       1,535  
SBA loan income   150       1,285       748  
Earnings on investment in life insurance   272       248       222  
Net loss on sale of MSRs   (159 )     (12 )     (52 )
Net loss on sale of loans         (184 )      
Net change in the fair value of derivative instruments   (51 )     197       149  
Net change in the fair value of loans held-for-sale   (380 )     112       102  
Net change in the fair value of loans held-for-investment   (39 )     86       170  
Net gain (loss) on hedging activity   18       (22 )     21  
Net gain on sale of investments AFS         453        
Other   969       1,059       1,036  
Total non-interest income   7,037       10,615       7,324  
Non-interest expense:          
Salaries and employee benefits   12,386       13,103       11,385  
Occupancy and equipment   1,183       1,210       1,338  
Professional fees   974       1,076       763  
Data processing and software   1,973       1,981       1,479  
Advertising and promotion   692       944       779  
Pennsylvania bank shares tax   258       224       269  
Other   2,692       3,120       2,730  
Total non-interest expense   20,158       21,658       18,743  
Income before income taxes   6,082       9,297       3,145  
Income tax expense   1,368       2,111       746  
Net income $ 4,714     $ 7,186     $ 2,399  
           
Basic earnings per common share $ 0.40     $ 0.62     $ 0.21  
Diluted earnings per common share $ 0.39     $ 0.61     $ 0.21  
           
Basic weighted average shares outstanding   11,811       11,543       11,205  
Diluted weighted average shares outstanding   12,153       11,771       11,446  

 
MERIDIAN CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CONDITION (Unaudited)

(Dollar amounts and shares in thousands, except per share amounts)
 
  March 31,

2026
  December 31,

2025
  September 30,

2025
  June 30,

2025
  March 31,

2025
Assets:                  
Cash and due from banks $ 12,458     $ 10,358     $ 12,605     $ 20,604     $ 16,976  
Interest-bearing deposits at other banks   15,811       25,420       27,384       29,570       113,620  
Federal funds sold                           629  
Cash and cash equivalents   28,269       35,778       39,989       50,174       131,225  
Securities available-for-sale, at fair value   196,012       193,457       194,268       187,902       185,221  
Securities held-to-maturity, at amortized cost   32,494       32,544       32,593       32,642       32,720  
Equity investments   2,137       2,166       2,150       2,130       2,126  
Mortgage loans held for sale, at fair value   38,960       33,762       28,016       44,078       28,047  
Loans and other finance receivables, net of fees and costs   2,185,442       2,170,600       2,162,845       2,108,250       2,071,675  
Allowance for credit losses   (21,625 )     (21,573 )     (21,794 )     (20,851 )     (20,827 )
Loans and other finance receivables, net of the allowance for credit losses   2,163,817       2,149,027       2,141,051       2,087,399       2,050,848  
Restricted investment in bank stock   7,699       7,811       8,350       9,162       8,369  
Bank premises and equipment, net   12,298       12,402       12,413       12,320       12,028  
Bank owned life insurance   30,959       30,687       30,421       30,175       29,935  
Accrued interest receivable   11,015       10,724       10,944       10,334       10,345  
OREO and other repossessed assets   6,009       5,997       3,714       3,148       249  
Deferred income taxes   4,548       4,215       4,989       5,314       5,136  
Servicing assets   3,694       3,932       3,845       3,658       4,284  
Goodwill   899       899       899       899       899  
Intangible assets   2,512       2,563       2,614       2,665       2,716  
Other assets   37,967       36,031       24,874       28,938       24,740  
Total assets $ 2,579,289     $ 2,561,995     $ 2,541,130     $ 2,510,938     $ 2,528,888  
                   
Liabilities:                  
Deposits:                  
Non-interest bearing $ 243,458     $ 245,377     $ 239,614     $ 237,042     $ 323,485  
Interest bearing:                  
Interest checking   157,151       157,360       151,973       173,865       161,055  
Money market and savings deposits   1,013,533       1,023,290       996,126       956,448       947,795  
Time deposits   755,818       732,101       743,403       743,019       696,407  
Total interest-bearing deposits   1,926,502       1,912,751       1,891,502       1,873,332       1,805,257  
Total deposits   2,169,960       2,158,128       2,131,116       2,110,374       2,128,742  
Borrowings   120,838       117,338       137,265       138,965       139,590  
Subordinated debentures   49,675       49,853       49,822       49,792       49,761  
Accrued interest payable   6,620       6,531       7,095       7,059       7,404  
Other liabilities   29,263       30,429       27,803       26,728       29,823  
Total liabilities   2,376,356       2,362,279       2,353,101       2,332,918       2,355,320  
                   
Stockholders’ equity:                  
Common stock   13,882       13,830       13,521       13,300       13,288  
Surplus   90,885       90,352       85,122       82,184       82,026  
Treasury stock   (26,079 )     (26,079 )     (26,079 )     (26,079 )     (26,079 )
Unearned common stock held by ESOP   (1,232 )     (1,232 )     (1,006 )     (1,006 )     (1,006 )
Retained earnings   131,180       128,124       122,376       117,132       112,952  
Accumulated other comprehensive loss   (5,703 )     (5,279 )     (5,905 )     (7,511 )     (7,613 )
Total stockholders’ equity   202,933       199,716       188,029       178,020       173,568  
Total liabilities and stockholders’ equity $ 2,579,289     $ 2,561,995     $ 2,541,130     $ 2,510,938     $ 2,528,888  

 
MERIDIAN CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND SEGMENT INFORMATION (Unaudited)
(Dollar amounts and shares in thousands, except per share amounts)
 
  Three Months Ended
  March 31,

2026
  December 31,

2025
  September 30,

2025
  June 30,

2025
  March 31,

2025
Interest income $ 40,712   $ 42,826   $ 43,109   $ 41,211   $ 39,168
Interest expense   17,510     19,199     19,993     20,052     19,392
Net interest income   23,202     23,627     23,116     21,159     19,776
Provision for credit losses   3,999     3,287     2,850     3,803     5,212
Non-interest income   7,037     10,615     9,953     11,288     7,324
Non-interest expense   20,158     21,658     21,546     21,357     18,743
Income before income tax expense   6,082     9,297     8,673     7,287     3,145
Income tax expense   1,368     2,111     2,014     1,695     746
Net Income $ 4,714   $ 7,186   $ 6,659   $ 5,592   $ 2,399
                   
Basic weighted average shares outstanding   11,811     11,543     11,325     11,228     11,205
Basic earnings per common share $ 0.40   $ 0.62   $ 0.59   $ 0.50   $ 0.21
                   
Diluted weighted average shares outstanding   12,153     11,771     11,540     11,392     11,446
Diluted earnings per common share $ 0.39   $ 0.61   $ 0.58   $ 0.49   $ 0.21

  Segment Information
  Three
Months Ended
March 31, 2026
  Three
Months Ended
March 31, 2025
(dollars in thousands) Bank   Wealth   Mortgage   Total   Bank   Wealth   Mortgage   Total
Net interest income $ 23,072     $ 60     $ 70     $ 23,202     $ 19,706     $ 9     $ 61     $ 19,776  
Provision for credit losses   3,999                   3,999       5,212                   5,212  
Net interest income after provision   19,073       60       70       19,203       14,494       9       61       14,564  
Non-interest income   1,398       1,729       3,910       7,037       1,912       1,535       3,877       7,324  
Non-interest expense   13,957       978       5,223       20,158       12,758       818       5,167       18,743  
Income before income taxes $ 6,514     $ 811     $ (1,243 )   $ 6,082     $ 3,648     $ 726     $ (1,229 )   $ 3,145  
Efficiency ratio   57 %     55 %     131 %     67 %     59 %     53 %     131 %     69 %



MERIDIAN CORPORATION AND SUBSIDIARIES

APPENDIX: NON-GAAP MEASURES (Unaudited)

(Dollar amounts and shares in thousands, except per share amounts)

Meridian believes that non-GAAP measures are meaningful because they reflect adjustments commonly made by management, investors, regulators and analysts. The non-GAAP disclosure have limitations as an analytical tool, should not be viewed as a substitute for performance and financial condition measures determined in accordance with GAAP, and should not be considered in isolation or as a substitute for analysis of Meridian’s results as reported under GAAP, nor is it necessarily comparable to non-GAAP performance measures that may be presented by other companies.

  Pre-Provision Net Revenue Reconciliation
  Three Months Ended
(Dollars in thousands, except per share data, Unaudited) March 31,

2026
  December 31,

2025
  March 31,

2025
Income before income tax expense $ 6,082   $ 9,297   $ 3,145
Provision for credit losses   3,999     3,287     5,212
Pre-provision net revenue $ 10,081   $ 12,584   $ 8,357

  Pre-Provision Net Revenue Reconciliation
  Three Months Ended
(Dollars in thousands, except per share data, Unaudited) March 31,

2026
  December 31,

2025
  March 31,

2025
Bank $ 10,513     $ 11,771   $ 8,860  
Wealth   811       493     726  
Mortgage   (1,243 )     320     (1,229 )
Pre-provision net revenue $ 10,081     $ 12,584   $ 8,357  

  Allowance For Credit Losses (ACL) to Loans and Other Finance Receivables, Excluding Loans at Fair Value
  March 31,

2026
  December 31,

2025
  September 30,

2025
  June 30,

2025
  March 31,

2025
Allowance for credit losses (GAAP) $ 21,625     $ 21,573     $ 21,794     $ 20,851     $ 20,827  
                   
Loans and other finance receivables (GAAP)   2,185,442       2,170,600       2,162,845       2,108,250       2,071,675  
Less: Loans at fair value   (14,090 )     (14,396 )     (14,454 )     (14,541 )     (14,182 )
Loans and other finance receivables, excluding loans at fair value (non-GAAP) $ 2,171,352     $ 2,156,204     $ 2,148,391     $ 2,093,709     $ 2,057,493  
                   
ACL to loans and other finance receivables (GAAP)   0.99 %     0.99 %     1.01 %     0.99 %     1.01 %
ACL to loans and other finance receivables, excluding loans at fair value (non-GAAP)   1.00 %     1.00 %     1.01 %     1.00 %     1.01 %

  Tangible Common Equity Ratio Reconciliation – Corporation
  March 31,

2026
  December 31,

2025
  September 30,

2025
  June 30,

2025
  March 31,

2025
Total stockholders’ equity (GAAP) $ 202,933     $ 199,716     $ 188,029     $ 178,020     $ 173,568  
Less: Goodwill and intangible assets   (3,411 )     (3,462 )     (3,513 )     (3,564 )     (3,615 )
Tangible common equity (non-GAAP)   199,522       196,254       184,516       174,456       169,953  
                   
Total assets (GAAP)   2,579,289       2,561,995       2,541,130       2,510,938       2,528,888  
Less: Goodwill and intangible assets   (3,411 )     (3,462 )     (3,513 )     (3,564 )     (3,615 )
Tangible assets (non-GAAP) $ 2,575,878     $ 2,558,533     $ 2,537,617     $ 2,507,374     $ 2,525,273  
Tangible common equity to tangible assets ratio – Corporation (non-GAAP)   7.75 %     7.67 %     7.27 %     6.96 %     6.73 %

  Tangible Common Equity Ratio Reconciliation – Bank
  March 31,

2026
  December 31,

2025
  September 30,

2025
  June 30,

2025
  March 31,

2025
Total stockholders’ equity (GAAP) $ 247,329     $ 244,064     $ 236,038     $ 228,127     $ 220,768  
Less: Goodwill and intangible assets   (3,411 )     (3,462 )     (3,513 )     (3,564 )     (3,615 )
Tangible common equity (non-GAAP)   243,918       240,602       232,525       224,563       217,153  
                   
Total assets (GAAP)   2,577,843       2,560,485       2,541,395       2,510,684       2,525,029  
Less: Goodwill and intangible assets   (3,411 )     (3,462 )     (3,513 )     (3,564 )     (3,615 )
Tangible assets (non-GAAP) $ 2,574,432     $ 2,557,023     $ 2,537,882     $ 2,507,120     $ 2,521,414  
Tangible common equity to tangible assets ratio – Bank (non-GAAP)   9.47 %     9.41 %     9.16 %     8.96 %     8.61 %
                   
  Tangible Book Value Reconciliation
  March 31,

2026
  December 31,

2025
  September 30,

2025
  June 30,

2025
  March 31,

2025
Book value per common share $ 17.09     $ 16.89     $ 16.33     $ 15.76     $ 15.38  
Less: Impact of goodwill /intangible assets   0.29       0.30       0.31       0.32       0.32  
Tangible book value per common share $ 16.80     $ 16.59     $ 16.02     $ 15.44     $ 15.06  

Contact:
Christopher J. Annas
484.568.5001
[email protected]



AMG to Announce First Quarter Results on May 1, 2026

Conference Call Scheduled for 8:00 a.m. Eastern Time

JUPITER, Fla., April 23, 2026 (GLOBE NEWSWIRE) — AMG (NYSE: AMG) will report financial and operating results for the first quarter ended March 31, 2026 on Friday, May 1, 2026. A conference call will be held at 8:00 a.m. Eastern time on the same day.

In addition to quarterly results, the conference call may include discussion of management’s expectations of future financial and operating results. Jay C. Horgen, President and Chief Executive Officer, and Dava E. Ritchea, Chief Financial Officer, will host the session.

Parties interested in listening to the conference call should dial 1-877-407-8291 (U.S. calls) or 1-201-689-8345 (non-U.S. calls) shortly before the call begins.

The conference call will also be available for replay beginning approximately one hour after the conclusion of the call. To hear a replay of the call, please dial 1-877-660-6853 (U.S. calls) or 1-201-612-7415 (non-U.S. calls) and provide conference ID 13759783. The live call and replay of the session, and a presentation highlighting the Company’s performance, can also be accessed via AMG’s website at https://ir.amg.com/.

For more information on AMG, please visit www.amg.com.

© 2026 Affiliated Managers Group, Inc. All rights reserved.

Investor & Media Relations:
Patricia Figueroa
+1 (617) 747-3300
[email protected]
[email protected]



Kuehn Law Encourages Investors of F5, Inc. to Contact Law Firm

NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) — Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of F5, Inc. (NASDAQ: FFIV) breached their fiduciary duties to shareholders.

According to a federal securities lawsuit, Insiders at F5 caused the company to misrepresent its cybersecurity capabilities while experiencing a persistent security breach of its BIG-IP product development environment. These statements included, among other things, touting best-in-class security offerings through September 2025 despite knowing of the breach discovered August 9, 2025.

If you currently own FFIV and purchased prior to October 28, 2024 please contact Justin Kuehn, Esq. by email at [email protected] or call (833) 672-0814.  Kuehn Law pays all case costs and does not charge its investor clients.Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

Why Your Participation Matters:

As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.

For additional information, please visit Shareholder Derivative Litigation – Kuehn Law.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts:
Kuehn Law, PLLC
Justin Kuehn, Esq.
53 Hill Street, Suite 605
Southampton, NY 11968
[email protected]
(833) 672-0814